Marisa Wexler, MS,  senior science writer—

The U.S. Food and Drug Administration (FDA) has given the go-ahead for a Phase 2 trial testing the inhalation therapy SPL84 in people with cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb C-to-T. Therapy developer Splisense welcomed the FDA’s clearance of the clinical trial, and…

For adults with cystic fibrosis (CF), the symptoms with the biggest impact on quality of life include pain, fatigue, shortness of breath, and mental health challenges, leading researchers to recommend routine screening to assist CF patients who could benefit from support. “Screening for prevalent symptoms that affect quality of life…

Bacteria in the airways of people with cystic fibrosis (CF) can interfere with the growth of Pseudomonas aeruginosa by secreting acetic acid, a main ingredient in vinegar. That’s according to “Airway commensal bacteria in cystic fibrosis inhibit the growth of P. aeruginosa via a released metabolite,”…

4D Molecular Therapeutics (4DMT) is planning a Phase 3 clinical trial that, if results are positive, will be the basis of applications seeking approval of the company’s inhaled gene therapy 4D-710 as a treatment for people with cystic fibrosis (CF) who can’t take CFTR modulators. 4DMT…

Sionna Therapeutics has raised $182 million in financing to advance the development of small molecules designed to restore CFTR protein function by binding to a specific part of the protein called the first nucleotide-binding domain, or NBD1. Cystic fibrosis (CF) is caused by mutations in the gene…

A lipid nanoparticle designed to deliver genetic therapy to lung cells could be used as a platform to treat lung-related diseases like cystic fibrosis (CF), a mouse study found. Researchers developed a way to identify lipid nanoparticles — fatty molecules that help deliver genetic material to cells — that…

A persistently stuffy nose is a big concern for people with cystic fibrosis (CF) who have chronic nose inflammation, but loss of smell isn’t as significant a worry, according to a new study that used the SinoNasal Outcome Test (SNOT-22). “Nasal congestion and post-nasal discharge were top priorities reported…

In the years after Kalydeco (ivakaftor) became available, the use of pancreatic enzyme replacement therapy (PERT) fell among people with cystic fibrosis (CF) in the U.S. who were eligible for the therapy. That’s according to “Pancreatic enzyme prescription following ivacaftor licensing: A retrospective analysis…

Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly reduced rates of colonization with the bacterium Pseudomonas aeruginosa in adults with cystic fibrosis (CF) at a center in Kentucky. Trikafta also reduced the need for mucus-clearing medicines and antibiotics, according to the study “Impact of Elexacaftor/tezacaftor/ivacaftor on Respiratory Colonization…

Compounds secreted by Lactobacillus, a group of bacteria commonly used in probiotics, are able to impede the growth of Pseudomonas aeruginosa isolated from the lungs of people with cystic fibrosis (CF). That’s according to the study, “Cell-free supernatants from Lactobacillus strains exert antibacterial, antibiofilm, and antivirulence…